【今日焦点】 乾燥综合征是一种慢性炎症性自身免疫性疾病，以淋巴细胞浸润和外分泌腺体损伤为主要特征。除唾液 腺和泪腺功能障碍导致的持续口乾、眼乾外，还可累及多系统器官。中国乾燥综合征的患病率为 0.3%-0.7%，且呈上升趋势，存在巨大尚未被满足的临床需求。 研究表明，自身反应性的B细胞过度活化是乾燥综合征发病的重要病理基础。泰它西普是由公司自主研 发的新型双靶融合蛋白，可同时靶向抑制B淋巴细胞刺激因子(BLyS)及增殖诱导配体(APRIL)的过度表 达，有效阻止B细胞异常分化与成熟，在临床和真实世界研究中展现出良好的疗效和安全性。 在中国，泰它西普获得《乾燥综合征超药品说明书用药中国临床实践指南》《B细胞靶向药物治疗风湿 免疫病中国专家共识》《原发性乾燥综合征多学科诊疗专家共识》等多项权威指南推荐。在国际上，泰 它西普的乾燥综合征适应症已获美国食品药物监督管理局授予的快速通道资格并获准开展全球多中心III 期临床试验。 【重大事项】 银诺医药-B(02591.HK)香港IPO发行价定为每股18.68港元 净筹6.3亿港元 帝王实业控股(01950.HK)与上海酒悦签署战略合作协议 共同拓展酒类及其他食品销售活 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不會就因本公佈全部或任何部分內容 而產生或因依賴該等內容而引致之任何損失承擔任何責任。 本公佈僅供參考，並不構成收購、購買或認購本公司任何證券之邀請或要約。 DIWANG INDUSTRIAL HOLDINGS LIMITED 帝 王 實 業 控 股 有 限 公 司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：1950） 自願性公告 最新業務發展 本公告乃由帝王實業控股有限公司（「本公司」）及其附屬公司（統稱「本集團」）自願作出， 以知會本公司股東及有意投資者有關本集團業務發展之最新消息。 戰略合作框架協議 經作出一切合理查詢後，就董事所知、所悉及所信，上海酒悅及彼等最終實益擁有人各 自均為獨立第三方。 合作事項 根據框架協議，本公司將與上海酒悅於中國共同成立一家合資公司（「合資公司」），專注 於精品酒水產品的營銷、分銷及相關供應鏈管理服務。新成立的合資公司將本公司於品牌、 資本及市場資源方面的優勢，以及上海酒悅優品在酒類供應鏈、分銷網絡及行業經驗上 — 1 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01950 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.0025 | USD | | 5,000,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 2,000,000,000 | USD | | 0.0025 | USD | | 5,000,000 | 本月底法定/註冊股本總額： USD 5,000,000 FF301 第 1 頁 共 10 頁 v 1.1 ...

帝王实业控股(01950)发布公告，张家伟先生辞任执行董事，自2025年7月31日起生效，以及委任钟汶龙 先生为执行董事，自2025年8月1日起生效。 ...

智通财经APP讯，帝王实业控股(01950)发布公告，张家伟先生辞任执行董事，自2025年7月31日起生 效，以及委任钟汶龙先生为执行董事，自2025年8月1日起生效。 ...

獨立非執行董事 區禧靖先生 李暢悅先生 黃振明先生 周筱春女士 DIWANG INDUSTRIAL HOLDINGS LIMITED 帝 王 實 業 控 股 有 限 公 司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：1950） 董事名單與其角色和職能 帝王實業控股有限公司董事（「董事」）會（「董事會」）之成員自2025年7月31日起生效，載列 如下： 執行董事 陳華先生 林錦洸先生 鍾汶龍先生（自2025年8月1日起生效） 孫金剛先生 香港，2025年7月31日 董事會設有三個董事委員會。下表提供各董事擔任有關委員會成員的資料。 | 董事 | 董事委員會 | | | | --- | --- | --- | --- | | | 審核委員會 薪酬委員會 | | 提名委員會 | | 陳華先生 | | M | | | 林錦洸先生 | | | M | | 區禧靖先生 | M | | M | | 黃振明先生 | M | | | | 李暢悅先生 | C | C | C | | 周筱春女士 | M | M | | 附註： C 指有關董事委員會的主席 M 指有關董事委員會的成員 ...

帝王實業控股有限公司（「本公司」，及其附屬公司「本集團」）之董事（「董事」）會（「董事會」） 謹此宣佈，張家偉先生（「張先生」）辭任執行董事，自2025年7月31日起生效，以及委任鍾 汶龍先生（「鍾先生」）為執行董事，自2025年8月1日起生效。 執行董事辭任 於2025年7月31日，張先生因有意投放更多時間於彼之其他事務而提出辭任執行董事，自 2025年7月31日起生效。 帝 王 實 業 控 股 有 限 公 司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：1950） 執行董事變動 香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 DIWANG INDUSTRIAL HOLDINGS LIMITED 張先生已向董事會確認，就其辭任而言，(i)並無向本公司提出申索；(ii)與董事會並無意 見分歧；及(iii)並無須提請香港聯合交易所有限公司及本公司股東垂注之事宜。 董事會謹借此機會對張先生於任職期間對本公司作出的寶貴貢獻表 ...

Group 1 - As of June 3, a total of 105 stocks reached their 52-week highs, with Huayin International Holdings (00989), Dingyifeng Holdings (00612), and Youquhui Holdings (02177) leading the high rate at 57.26%, 37.93%, and 23.02% respectively [1] - The closing prices and highest prices for the top three stocks are as follows: Huayin International Holdings at 1.370 and 1.950, Dingyifeng Holdings at 0.770 and 0.800, and Youquhui Holdings at 3.550 and 3.580 [1] - Other notable stocks that reached their 52-week highs include China Antibody-B (03681) with a high rate of 21.62% and Fengcheng Holdings (02295) at 19.52% [1] Group 2 - The report also lists stocks that reached their 52-week lows, with Des Holdings (08437) showing the largest decline at -38.79%, followed by Dimi Life Holdings (01667) at -20.50% [3] - The closing prices and lowest prices for the top three stocks that reached their lows are: Des Holdings at 0.177 and 0.071, Dimi Life Holdings at 0.140 and 0.128, and Lujizhi Technology (01745) at 0.197 and 0.194 [3] - Other stocks with significant declines include GBA Group (00261) at -11.48% and Baide International (02668) at -10.88% [3]

Financial Performance - For the year ended December 31, 2024, the Group's revenue was approximately RMB566,475,000, a slight decrease of 0.72% compared to RMB570,572,000 in 2023[15]. - The Group's gross profit increased by approximately RMB23,916,000 or 10.3%, reaching RMB257,299,000 for the year[15]. - The net profit for the year was approximately RMB30,015,000, compared to RMB24,874,000 in the prior year, with profit attributable to owners of the Company at RMB30,030,000[16]. - Basic and diluted earnings per share were RMB4.17 cents, an increase from RMB4.11 cents in 2023[16]. - The Board has resolved not to declare a final dividend for the year[17]. Business Segments - The Faux Leather Chemicals Business remained stable due to increased sales and marketing efforts, while the Chinese Liquor Business continued to grow, contributing significantly to revenue[22]. - The revenue from the Faux Leather Chemicals Business was approximately RMB262,495,000, remaining stable compared to the previous year[33]. - The gross profit margin for the Faux Leather Chemicals Business was approximately 21.2%, slightly up from 21.1% in the prior year[34]. - Revenue from the Chinese Liquor Business decreased by approximately RMB4,060,000 or 1.31%, totaling approximately RMB303,980,000 for the year[44]. - The gross profit for the Chinese Liquor Business was approximately RMB201,598,000, an increase from RMB177,894,000 in the previous year[44]. - The segment profit for the Chinese Liquor Business was approximately RMB29,669,000, up from RMB23,407,000 in the prior year[44]. Market Outlook and Strategy - The Chinese economy is expected to rebound in 2024, with GDP growth projected at 5-6%, supported by government stimulus and increased domestic consumption[21]. - The company plans to shift focus from the Faux Leather Chemicals Business to the growing Chinese liquor market due to evolving consumer preferences[27]. - The company aims to enhance brand position in the Chinese liquor industry through strategic partnerships with e-commerce platforms[27]. - The Chinese liquor market is seen as a significant growth opportunity, with a focus on product development and market research[29]. Financial Position and Capital Management - As of December 31, 2024, the Group's current assets were approximately RMB 557,411,000, an increase from RMB 548,637,000 as of December 31, 2023[58]. - The current liabilities increased to approximately RMB 155,653,000 from RMB 95,582,000 as of December 31, 2023[58]. - The current ratio decreased from approximately 5.74 times as of December 31, 2023, to approximately 3.58 times as of December 31, 2024[58]. - Bank borrowings increased to approximately RMB 64,500,000 from RMB 25,000,000 in the previous year[59]. - The Group's capital expenditure was approximately RMB 127,301,000, representing an increase of RMB 112,318,000 compared to RMB 14,983,000 in the prior year[61]. - The gearing ratio as of December 31, 2024, was recorded at 1.01%, compared to a net cash position in the previous year[60]. Share Capital and Rights Issue - The company issued 432,000,000 rights shares at a subscription price of HK$0.67 per share, raising approximately HK$289,440,000[73]. - The net proceeds from the rights issue, after deducting estimated expenses, were approximately HK$286.55 million, representing a net price of approximately HK$0.663 per rights share[74]. - Following the share consolidation effective on May 30, 2023, the authorized share capital increased from US$1,000,000 to US$5,000,000, divided into 2,000,000,000 consolidated shares[71]. - The number of shares in issue became 720,000,000 of par value US$0.0025 each after the completion of the rights issue on July 28, 2023[78]. Governance and Management - The company has appointed independent non-executive directors with diverse backgrounds in finance, engineering, and alcohol-related technology, enhancing its governance structure[121]. - The company is focused on expanding its market presence through strategic appointments and leveraging the expertise of its directors[124]. - The company aims to enhance its product quality and management through the expertise of its independent directors in their respective fields[126]. - The company is committed to maintaining high standards in corporate governance and risk management through its experienced board members[125]. Risks and Compliance - The Group's principal business activities include the manufacturing and sales of faux leather chemicals and Chinese liquor, with significant risks related to product quality and production security[134]. - Financial risks faced by the Group include interest rate and exchange rate risks, equity price risk, credit risk, and liquidity risk[135]. - The Group has maintained compliance with applicable laws and regulations in the PRC, with no incidents of material non-compliance reported[145]. - The Group's environmental policies focus on sustainability and societal development, as detailed in the Environmental, Social, and Governance Report[144]. Employee and Community Engagement - The group had a total of 217 employees as of December 31, 2024, an increase from 208 in 2023, and offers competitive remuneration packages[101][105]. - Charitable donations made by the Group during the Reporting Period totaled approximately RMB411,000, down from RMB515,000 in the previous year[163]. Investments and Transactions - The group did not have any significant investments as no single investment accounted for 5% or more of the total assets as of December 31, 2024[88][92]. - The fair value loss for listed securities in Hong Kong for the year ended December 31, 2024, was RMB1,018,000, with an unrealized fair value loss of RMB969,000[94]. - The company agreed to sell 25% of the issued share capital of Darkblue Investment Ltd. for a consideration of RMB20,840,000, payable in cash installments[106].

Financial Performance - For the fiscal year ending December 31, 2024, the company's revenue slightly decreased by approximately RMB 4,097,000 or 0.72%, totaling approximately RMB 566,475,000 compared to RMB 570,572,000 in 2023[3] - The gross profit for the fiscal year increased by approximately RMB 23,916,000 or 10.3%, amounting to approximately RMB 257,299,000, up from RMB 233,383,000 in the previous year[3] - The net profit for the fiscal year was approximately RMB 30,015,000, compared to RMB 24,874,000 in the previous year, with profit attributable to the company's owners at approximately RMB 30,030,000, up from RMB 19,451,000[3] - Basic and diluted earnings per share for the fiscal year were RMB 4.17, compared to RMB 4.11 in 2023[4] - Total comprehensive income for the year was RMB 30,173,000, compared to RMB 24,623,000 in the previous year[7] - The total segment profit for the group was RMB 43,939,000, slightly down from RMB 44,912,000 in the previous year[27] - For the year ended December 31, 2024, the company reported a pre-tax profit of RMB 5,067,000, an increase of 39.5% compared to RMB 3,632,000 in 2023[40] - The total tax expense for the year was RMB 5,489,000, a decrease of 49.0% from RMB 10,763,000 in 2023, primarily due to a reduction in current income tax[42] Assets and Liabilities - Non-current assets increased to RMB 270,273,000 from RMB 188,954,000 in the previous year, primarily due to increases in property, plant, and equipment[8] - Current assets totaled RMB 557,411,000, slightly up from RMB 548,637,000 in 2023[8] - The company's total equity increased to RMB 668,744,000 from RMB 638,586,000 in the previous year[9] - Total assets increased to RMB 827,684,000 in 2024 from RMB 737,591,000 in 2023, representing an increase of 12.2%[29] - The total liabilities rose to RMB 158,940,000 in 2024, compared to RMB 99,005,000 in 2023, marking a significant increase of 60.3%[29] - Trade receivables as of December 31, 2024, totaled RMB 237,089,000, an increase from RMB 232,613,000 in 2023, while the impairment provision for trade receivables rose to RMB 15,923,000 from RMB 9,270,000[49][50] - Trade payables increased to RMB 41,586,000 in 2024 from RMB 39,176,000 in 2023, representing a growth of approximately 6.5%[52] - The group's current liabilities as of December 31, 2024, were approximately RMB 155,653,000, up from RMB 95,582,000 on December 31, 2023[73] - The current ratio decreased from approximately 5.74 times on December 31, 2023, to approximately 3.58 times on December 31, 2024[73] - The debt-to-equity ratio as of December 31, 2024, was recorded at 1.01%, compared to a net cash position on December 31, 2023[74] Capital Expenditures and Investments - Capital expenditures for the artificial leather chemical business were RMB 92,301,000, while the white liquor business had capital expenditures of RMB 35,000,000, totaling RMB 127,301,000[30] - The group's capital expenditure for the year was approximately RMB 127,301,000, a significant increase of RMB 112,318,000 compared to RMB 14,983,000 in the previous year[75] - The company issued 432,000,000 rights shares at a price of HKD 0.67 each, raising approximately RMB 263,580,000 to support its liquor and artificial leather chemical businesses[62] - The net proceeds from the rights issue amount to HKD 286,550,000, allocated for various business developments including HKD 20,000,000 for opening Chinese-style taverns and HKD 100,000,000 for large-scale advertising campaigns in China[83] - As of December 31, 2024, the group's investment in listed company shares has a total book value of approximately RMB 5,972,000 (approximately HKD 6,449,000), with no significant investments exceeding 5% of total assets[86] Revenue Breakdown - The external sales for the artificial leather chemical business were RMB 262,495,000, while the white liquor business generated RMB 303,980,000[27] - Revenue from overseas markets was RMB 4,738,000, a decrease from RMB 6,808,000 in 2023, reflecting a decline of 30.4%[32] - Revenue from the artificial leather chemical business was approximately RMB 262,495,000, remaining stable compared to RMB 262,546,000 in 2023, with a gross profit of RMB 55,700,000[64] - Revenue from the liquor business decreased slightly by RMB 4,060,000 or 1.31%, totaling approximately RMB 303,980,000 for the year[67] Expenses and Financial Management - Interest expenses from bank borrowings increased significantly to RMB 1,400,000 in 2024, compared to RMB 688,000 in 2023, reflecting a rise of 103.5%[39] - Research and development expenses amounted to RMB 8,977,000 for the artificial leather chemical business, indicating ongoing investment in innovation[30] - Research and development expenses for the year were RMB 8,977,000, a slight decrease from RMB 9,725,000 in 2023, indicating a focus on cost management[41] - The company’s advertising expenses increased to RMB 162,362,000 in 2024 from RMB 148,099,000 in 2023, reflecting a strategic push in marketing efforts[41] Corporate Governance and Compliance - The board of directors has resolved not to declare a final dividend for the fiscal year[5] - The company did not declare or recommend any dividends for the year ended December 31, 2024, consistent with the previous year[46] - The group has not early adopted new or revised International Financial Reporting Standards (IFRS) that have been issued but are not yet effective, indicating no significant expected impact on the consolidated financial statements[18] - The audit committee, consisting of four independent non-executive directors, has reviewed the annual performance and accounting policies for the year ending December 31, 2024[101] - The annual performance announcement and annual report will be published on the Hong Kong Stock Exchange and the company's website[102] Strategic Initiatives - The company plans to promote its liquor products through advertising at airports and train stations, as well as hosting tasting events and exhibitions in China[67] - The group plans to expand its product offerings in the artificial leather chemicals and liquor business segments to cover a broader customer base[71] - The liquor business will be rebranded under the names "Emperor Pool" and "Emperor Dragon Pool" starting September 2023, targeting specific customer segments[72] - The group aims to enhance its market share through strengthened marketing activities in response to increased competition in the recovering Chinese consumer market[71] Risk Management - The group is exploring measures to manage foreign exchange risks, as sales and purchases are primarily denominated in RMB[90] - The group has no significant contingent liabilities or guarantees recorded as of December 31, 2024[89]